Brainomix任命Khush F. Mehta为主席，以支持全球扩张和商业增长-动脉网

Brainomix Appoints Khush F. Mehta as Chair to Support Global Expansion and Commercial Growth

CISION 等信源发布 2025-05-21 16:00



可切换为仅中文







OXFORD, England

牛津，英格兰

and

和

CHICAGO

芝加哥

，

May 21, 2025

2025年5月21日

/PRNewswire/ -- Brainomix, a global leader in AI-powered imaging solutions in stroke and lung fibrosis, today announced the appointment of

/PRNewswire/ -- Brainomix，一家在中风和肺纤维化领域的人工智能影像解决方案的全球领导者，今天宣布任命

Khush F. Mehta

库什·F·梅塔

as Chair of the Board. He succeeds Professor Jacqueline ('Jackie') Hunter CBE, who has served as Chair for the past five years.

作为董事会主席，他接替了在过去五年中担任主席的杰奎琳（“杰基”）·亨特教授CBE。

继续阅读

Khush F. Mehta, Chair of Brainomix

脑诺米克斯公司董事长库什·F·梅塔

Khush brings more than two decades of global strategic and operational leadership in healthcare, having recently served as Chairman of Arterys, a pioneer of AI in medical imaging, which was acquired by Tempus AI in 2022. Prior to this, Khush was the Chief Strategy Officer at Siemens Healthcare, the head of the company for .

库什在医疗保健领域拥有二十多年全球战略和运营领导经验，最近曾担任医疗影像AI先驱公司Arterys的董事长，该公司于2022年被Tempus AI收购。在此之前，库什曾任西门子医疗的首席战略官。

Asia Pacific

亚太地区

and also held various leadership roles in the US and

并且还在美国担任过各种领导职务和角色

Germany

德国

. He has an MBA from the Yale School of Management and a Master's degree in Commerce and Financial Management from Sydenham College in

他拥有耶鲁管理学院的工商管理硕士学位，以及锡德纳姆学院的商业和金融管理硕士学位。

Mumbai

孟买

。

Based in the US, Khush will support Brainomix's continued internationalization, helping guide its next phase of growth as it deepens its presence in the US and explores new markets for its AI imaging solutions in stroke and lung fibrosis.

总部位于美国的Khush将支持Brainomix的持续国际化，帮助引导其下一阶段的增长，因为它加深了在美国的存在，并为其在中风和肺纤维化方面的人工智能成像解决方案探索新市场。

The appointment follows the company's recent £14M (

该任命是在公司近期获得1400万英镑（

$18M

1800万美元

)

Series C investment

C轮融资

, which provides the resources to accelerate commercial expansion of its stroke platform in the US and international markets. Brainomix recently secured a

，这为其在美国和国际市场上加速中风平台的商业扩展提供了资源。Brainomix最近获得了

major FDA clearance

主要的FDA许可

for a novel and patented feature in its Brainomix 360 platform, reinforcing its position as a leader in the AI imaging space.

由于其Brainomix 360平台中的一项新颖且获得专利的功能，进一步巩固了其在AI成像领域的领导地位。

博士

Michalis Papadakis

米哈利斯·帕帕达基斯

, CEO and Co-Founder at Brainomix, said,

Brainomix 的首席执行官兼联合创始人表示，

'We are delighted to welcome Khush as Chair at a pivotal growth stage for Brainomix. His extensive leadership across international markets, coupled with his deep expertise in healthcare AI, makes him an ideal Chair to help navigate our further global expansion. As we scale our impact across stroke and lung disease, his guidance will be invaluable in driving forward our mission to improve outcomes for patients worldwide.'.

“我们非常高兴在Brainomix的关键增长阶段迎来Khush担任主席。他在国际市场的广泛领导经验，加上在医疗人工智能领域的深厚专业知识，使他成为帮助我们进一步推动全球扩展的理想主席。随着我们在中风和肺病领域扩大影响力，他的指导将对推动我们改善全球患者预后的使命至关重要。”

'I would like to thank Jackie for her excellent mentorship and strategic leadership through critical early stages of our growth. During her time as Chair, Brainomix has more than doubled in size and delivered on our ambitions to secure widespread adoption of our stroke platform, advance our e-Lung platform and expand beyond the UK into international markets, including the US.'.

“我要感谢杰基在我们成长的关键早期阶段给予的出色指导和战略领导。在她担任主席期间，Brainomix的规模增加了一倍多，并实现了我们的雄心壮志，包括确保我们的中风平台得到广泛采用、推进我们的e-Lung平台，并拓展到英国以外的国际市场，包括美国。”

Khush F. Mehta

库什·F·梅塔

, Chair of Brainomix, said,

, Brainomix主席表示，

'Brainomix has developed one of the most clinically impactful AI platforms, with demonstrative real-world data showing a transformative effect on stroke care. I'm honored to support the company in its next chapter, as it expands into new geographies and therapeutic areas. With a strong foundation in .

“Brainomix开发了最具临床影响力的AI平台之一，有实际数据证明其对中风护理的变革性影响。我很荣幸能够支持公司进入下一个篇章，因为它正在扩展到新的地理区域和治疗领域。公司在...

Europe

欧洲

and an growing footprint in the US, Brainomix is uniquely positioned to become a global leader in healthcare AI.'

并且在美国的影响力日益扩大，Brainomix有望成为医疗保健AI领域的全球领导者。

Prof

教授

Jackie Hunter CBE

杰基·亨特女士勋章获得者

, Outgoing Chair of Brainomix, said,

，Brainomix即将卸任的主席表示，

'The past five years have been a very exciting time for Brainomix, as we successfully progressed from a start-up to an established scale-up. We have seen extensive clinical adoption of our Brainomix 360 Stroke tool, and have expanded our footprint in Life Sciences, securing a number of strategic partnerships with leading global pharma companies who recognize the distinct value of our cutting-edge technology.

“过去的五年对Brainomix来说是非常激动人心的时期，因为我们成功地从一家初创公司发展成为一家成熟的成长型公司。我们的Brainomix 360 Stroke工具在临床上得到了广泛采用，并且我们在生命科学领域扩展了影响力，与多家全球领先的制药公司建立了战略合作伙伴关系，这些公司认识到我们尖端技术的独特价值。

I am excited to see the world-class team at Brainomix continue to deliver positive impact for patients globally.'.

我非常兴奋地看到Brainomix的世界级团队继续为全球患者带来积极的影响。

Andrew Barker

安德鲁·巴克

, Brainomix's first Chair and most recently Founder Director, has retired from the Board. Andrew's leadership and guidance was integral to the company's evolution from an aspiring

，Brainomix的第一任主席兼最近的创始人董事，已从董事会退休。安德鲁的领导和指导对公司从一个渴望发展的公司演变过程中起到了关键作用。

University of Oxford

牛津大学

spin-out to a successful start-up robustly positioned for sustained success.

分拆为一家成功起步的初创公司，具备稳健的持续成功定位。

Notes to Editors

编辑须知

About Brainomix

关于Brainomix

Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spinout from the University of

Brainomix 专注于开发人工智能驱动的软件解决方案，以实现精准医疗，从而为中风和肺纤维化提供更好的治疗决策。该公司起源于牛津大学的衍生公司。

Oxford

牛津

, Brainomix is an expanding commercial-stage company with offices in the UK,

，Brainomix是一家在英国设有办事处的、处于商业化阶段的扩展型公司，

Ireland

爱尔兰

and the

和

USA

美国

, and operations in more than 20 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients..

，并在 20 多个国家开展业务。Brainomix 是一家私人公司，得到了领先的健康科技投资者的支持，创新了屡获殊荣的成像生物标志物和软件解决方案，这些解决方案已在世界数百家医院得到临床应用。其第一款产品 Brainomix 360 卒中平台为临床医生提供了最全面的卒中成像解决方案，提高了治疗率并改善了患者的功能独立性。

To learn more about Brainomix and its technology visit

要了解有关Brainomix及其技术的更多信息，请访问

www.brainomix.com

, and follow us on

，关注我们

Twitter

，

领英

and

和

Facebook

。